secwatch.observer — SEC 8-K summary
======================================

Issuer:     AETHLON MEDICAL INC (AEMD)
CIK:        0000882291
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001683168-24-005445
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aethlon Medical receives second ethics approval for Hemopurifier cancer trial in Australia
--------------------------------------------------------------------------------

- Bellberry Human Research Ethics Committee granted full ethics approval to Pindara Private Hospital for Hemopurifier trial in solid tumors not responding to anti-PD-1 antibodies.
- This is the second ethics committee approval; the first came from Royal Adelaide Hospital in June 2024.
- The trial will be conducted by Dr. Marco Matos at Pindara Private Hospital in Queensland, Australia.
- Next steps include Research Governance Office approval, then Site Initiation Visits before patient enrollment can begin.
- Primary endpoint is safety; the trial plans to enroll 9–18 patients and will explore extracellular vesicle reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882291/000168316824005445/0001683168-24-005445-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882291/000168316824005445/aethlon_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-005445

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer